Home Archives 2013

Yearly Archives: 2013

journal-of-commercial-biotechnology_160Made available by the elective open access option at the Journal of Commercial Biotechnology, this paper is free to view without subscription:

Assessing the history and value of Human Genome Sciences
Laura M. McNamee, Fred D Ledley

Abstract

Human Genome Science (HGS) aspired to dominate the emergent field of genomics by discovering expressed gene sequences and developing therapeutic and diagnostic products based on proprietary genes. While HGS’ accomplishments fell short of their own lofty expectations, by the time HGS was acquired by GlaxoSmithKline, the company had extensive intellectual property and had launched a product with >$1 billion market potential. Nevertheless, HGS’ acquisition price was less than the total capital investments in the company. This work examines HGS’ history and accomplishments in the context of the business plan described by the company at their IPO. We focus specifically on the company’s valuation over time, which was highly correlated with general market indices, but negatively correlated with metrics of technical or clinical progress. The history of HGS points to the challenge of accounting for the value created by a science-based business plan. Earnings-based metrics, present value calculations, and “fair value” assessments did not account for HGS’ progress in executing their stated business plan. This work highlights the critical need for accounting practices that credit value to the progress of translational science and enable investors to profit from such investments.

In addition to hosting a comprehensive database of drug and patent-related information, DrugPatentWatch also is also a source for old versions of the FDA Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations. More information is available in the Report Store, or you use the direct links below:

1995 Orange Book

1998 Orange Book

1999 Orange Book

2005 Orange Book

2006 Orange Book

2007 Orange Book

2008 Orange Book

2009 Orange Book

2010 Orange Book

2011 Orange Book

2012 Orange Book

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for October 1 2013

TradenameApplicantGeneric NamePatent Expiration
OMNISCAN
Ge Healthcare
gadodiamide
Oct 1, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Future drug patent expirations by month

How Many Drug Patents Will Expire in the Coming Months?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for September 30 2013

TradenameApplicantGeneric NamePatent Expiration
LEVULAN
Dusa
aminolevulinic acid hydrochloride
Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KIT
Vyteris
epinephrine; lidocaine hydrochloride
Sep 30, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which pharmaceutical companies recieved the most drug approvals last
year

Which Companies had the Most Drug Approvals Last Year?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

On a recent press tour of the Berlin and Saxony region I came across something I wasn’t expecting. Germany has instituted a set of very progressive (or, aggressive) policies to phase out nuclear and carbon-based energy in favor of renewable sources. I saw a lot of interesting wind, solar, and other projects (more on these later), but also saw something I really wasn’t expecting — a large group of Libyan engineers learning about these renewable energy sources and how to integrate them with existing power grids.

libyan windfarmMy immediate question was “why would an oil-rich country like Libya be interested in developing renewable energy?” The answers were illuminating.

“We only have 50 years of oil left” was the first answer. With the Libyan political system currently in turmoil, it is impressive that there are stakeholders looking for sustainable means to promote stability. Much support comes from EU funding to North African nations to supply renewable energy to proximal member states such as Spain and Italy. It is worth noting that the potential for solar, and likely wind energy, in Libya far exceeds the oil resources–Germany has made great investments in solar energy, but they are limited by solar exposure similar to that of Alaska. North African countries have longer photoperiods with less seasonality, and less cloud cover. The large unpopulated areas also mean fewer siting problems (and great opportunities for economic development outside urban areas).

Another rationale presented is that oil resources are currently used to generate electricity in Libya. Finding alternative means to produce electricity can increase the amount of oil that Libya can sell, ultimately improving the country’s wealth. Furthermore, great efforts are necessary to ensure that remote habitations are supplied with electricity. Setting up independent power grids can avoid long, lossy, runs of electricity.

A final rationale is that production of energy from non-oil resources holds the potential to decrease the political power of foreign oil extraction firms.

I will follow up in a future with more on my general observations and thoughts on Germany’s energy policies.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for September 29 2013

TradenameApplicantGeneric NamePatent Expiration
COMBIVENT RESPIMAT
Boehringer Ingelheim
albuterol sulfate; ipratropium bromide
Sep 29, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which pharmaceutical companies listed the most drug patents last
year

Which Companies Listed the Most Drug Patents Last Year?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Distribution of data and unique material resources made with NIH funding

Go to paper

ABSTRACT: The research community, particularly in academic and public sector institutions, recognises that scientists have an obligation to publish the results of their research and otherwise make available data or unique materials that are necessary for others to replicate or advance their research. Over the past 15 years, the US National Institutes of Health (NIH) has developed policies to make such obligations a requirement for recipients of NIH funding...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for September 28 2013

TradenameApplicantGeneric NamePatent Expiration
ELIGARD
Tolmar Therap
leuprolide acetate
Sep 28, 2013
NOVOLOG MIX 50/50
Novo Nordisk Inc
insulin aspart protamine recombinant; insulin aspart recombinant
Sep 28, 2013
NOVOLOG MIX 70/30
Novo Nordisk Inc
insulin aspart protamine recombinant; insulin aspart recombinant
Sep 28, 2013
NOVOLOG MIX 70/30 FLEXPEN
Novo Nordisk Inc
insulin aspart protamine recombinant; insulin aspart recombinant
Sep 28, 2013
NOVOLOG MIX 70/30 PENFILL
Novo Nordisk Inc
insulin aspart protamine recombinant; insulin aspart recombinant
Sep 28, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Future drug patent expirations by month

How Many Drug Patents Will Expire in the Coming Months?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

Pharmaceutical companies are actively exploring new sourcing strategies to address the continuing decline in R&D productivity. Fragmented outsourcing has not sufficiently solved the problem, so leaders are moving toward an integrated sourcing model that blends control of the development pipeline with the economies of scalable outsourcing. While many pharmaceutical companies recognize the potential value of this approach, few are prepared to fully exploit it. Accenture has identified four criteria to help pharmaceutical companies successfully increase R&D productivity through integrated outsourcing. Making the necessary changes will not be easy, and individual companies will have to determine the appropriate roadmap they each need to use.   

The safety and efficacy of America’s medicine supply has long been considered the “gold standard” by which other countries are measured.  Our “closed system” comprised of strict regulations for the approval, manufacture and distribution of prescription drugs served us well in an era when those regulations could be enforced.  Today, however, a global economy through which goods and services flow virtually unimpeded, and the ever-increasing demand for more accessible and affordable prescription drugs are threatening to overwhelm our regulatory systems and place the medicine supply at risk.  The growing presence of substandard, adulterated and counterfeit medicine in the U. S. market is a warning sign that responsible parties need to act promptly to restore the overall integrity of the nation’s prescription drug supply.  This will require a holistic approach that employs advanced technology within a comprehensive strategy that includes stakeholder awareness, regulatory enforcement, legal change, and a sustained policy commitment to patient safety and global health.